This is a clinical trial of pergolide mesylate in patients with prolactin secreting pituitary tumors who have had a previous trial of bromocriotine that was ineffective in decreasing serum prolactin levels. The trial requires tests before, during and after daily administration of pergolide for one year. These tests are needed to determine any side effects, prolactin levels, and tumor size.
Streeten, D H (1995) Idiopathic edema. Pathogenesis, clinical features, and treatment. Endocrinol Metab Clin North Am 24:531-47 |
Breslau, N A; Weinstock, R S (1988) Regulation of 1,25 (OH)2D synthesis in hypoparathyroidism and pseudohypoparathyroidism. Am J Physiol 255:E730-6 |
Haas, D C; Anderson Jr, G H; Streeten, D H (1985) Role of angiotensin in lethal cerebral hypoperfusion during treatment of acute hypertension. Arch Intern Med 145:1922-4 |